Drugs | Mechanism of action | Brand name | Clinical indications | Half-life | Elimination | Drug interactions (see Table 2) |
---|---|---|---|---|---|---|
Dabigatran | Direct thrombin inhibitor | Pradaxa | - Non-valvular AFib; | 12–14 h | Renal (80%) | - P-gp inducers |
- Treatment of DVT and PE; | - P-gp inhibitors | |||||
- Reduction in the risk of recurrence of DVT and PE. | ||||||
Rivaroxaban | Factor Xa inhibitor | Xarelto | - Non-valvular AFib; | 5–13 h | Renal (67%) | - Combined P-gp and strong CYP3A4 inhibitors and inducers |
- Treatment of DVT and PE; | ||||||
- Reduction in the risk of recurrence of DVT and PE; | ||||||
- Prophylaxis of DVT following hip or knee replacement surgery; | ||||||
- Prophylaxis of DVT and PE in acutely ill medical patients; | ||||||
- Risk reduction of major cardiovascular events in stable atherosclerotic vascular disease (in combination with ASA). | ||||||
Apixaban | Factor Xa inhibitor | Eliquis | - Non-valvular AFib; | 12 h | Faecal (56%) | - Strong dual inhibitors of P-gp and CYP3A4 |
- Treatment of DVT and PE; | ||||||
- Prophylaxis of DVT following hip or knee replacement surgery. | ||||||
Edoxaban | Factor Xa inhibitor | Savaysa (USA) / Lixiana (Brazil) | - Non-valvular AFib; | 10–14 h | Renal (50%) | - P-gp inducers and inhibitors. |
- Treatment of DVT and PE following 5–10 days of initial parenteral anticoagulation. |